CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01964430
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:05.833393+00:00
Published At: 2020-01-06T00:00:00+00:00
Record Updated At: 2023-06-28
Results Posted At: 2020-01-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Neoplasms", "Digestive System Neoplasms", "Neoplasms by Site", "Neoplasms", "Endocrine Gland Neoplasms", "Pancreatic Diseases", "Digestive System Diseases", "Endocrine System Diseases", "Gemcitabine", "Antimetabolites, Antineoplastic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-06-28"
protocolSection.identificationModule.nctId: "NCT01964430"
protocolSection.identificationModule.officialTitle: "A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-01-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.